Advertisement
Home »

NICHE-3 Demonstrates Equally Impressive Results as NICHE-2

Oct 27, 2023

REFERENCES & ADDITIONAL READING

Chalabi M, et al. Ann Oncol. 2022;33(suppl 7):S1389.

 

Amaria RN, et al. Nature 2022;611:155–160.

 

Verschoor YL, et al. Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: The NICHE-3 study. Abstract LBA31, ESMO 2023, 20–24 October, Madrid, Spain.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement